Genitourinary Cancers Clinical Trials & Research at Providence Medical Group

Genitourinary (GU) cancers encompass a diverse group of malignancies affecting the urinary system and the male reproductive organs. This category includes cancers of the bladder, kidneys, prostate, testicles, and penis. These cancers vary widely in their biology, prognosis, and treatment options, making clinical research crucial for improving patient outcomes.

Clinical trials are fundamental to the advancement of GU cancer treatment. These studies investigate new therapies and interventions, aiming to enhance the effectiveness and reduce the side effects of existing treatments. They encompass a wide range of approaches, including novel drug therapies, immunotherapies, targeted treatments, surgical techniques, and combinations of these modalities.

Prostate/Endometrial and Pancreatic cancer studies are also included in these trials.

Pancreatic cancer develops in the pancreatic ductal, acinar, and islet cells. Most pancreatic cancers are adenocarcinoma of pancreatic ductal (PDA) origin. Pancreatic cancer accounts for about 3 percent of all cancers in the U.S. Risk factors that can be changed include tobacco use, obesity, and workplace exposure to certain chemicals.

Providence Medical Group is currently enrolling patients for the following genitourinary cancers clinical trials:

(Currently Suspended)
NRG-GU010 Guidance Study Phase III Randomized Trial of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation

Treatment agent: Radiotherapy +/- Androgen Deprivation Therapy (ADT)
Physician: Michael N. Corradetti
Study Coordinator: Beatrice Becker // beatrice.becker@providence.org // 707-932-5164
Study Resources: https://clinicaltrials.gov/study/NCT03488693
Sponsor: National Cancer Institute (NCI) / NRG Oncology Clinical Trials
​Location: Providence Queen of the Valley Medical Center, Napa, CA

Study for participants with metastatic Stage IV castration- sensitive prostate cancer (Evopar)

Treatment agent: AZD5305 in Combination with Physician’s Choice New Hormonal Agents
Physician: Dr Wes Lee
Study Coordinator: Teresa Lund // teresa.lund@stjoe.org // 707-521-3830
Study Resources: Study Details | Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents | ClinicalTrials.gov
Sponsor: AstraZeneca
Location: Providence Cancer Center, Santa Rosa, CA

Study for participants with locally advanced unresectable or metastatic pancreatic tumors expressing CLDN18.2 (Clarity- TP01)

Treatment agent: AZD0901 as monotherapy and in combination with anti-cancer agents
Physician: Dr. Ian Anderson
Study Coordinator: Teresa Lund // teresa.lund@stjoe.org // 707-521-3830
Study Resources: Study Details | AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | ClinicalTrials.gov
Sponsor: AstraZeneca
Location: Providence Cancer Center, Santa Rosa, CA

EMD Serono MS201924-0020 (DDriver solid tumors 320)- Metastatic or Locally Advanced Unresectable solid tumors. Prostate/Endometrial Cancer

Treatment agent: (Open label): M1774, M4076 (orals) + Avelumab (IV)
Physician: Ian Anderson, MD
Study Coordinator: Teresa Lund // teresa.lund@stjoe.org // 707-521-3830
Study Resources: Abstract CT063: Phase Ib trial of ATR inhibitor (ATRi) tuvusertib + ATM inhibitor (ATMi) lartesertib (M4076) in patients (pts) with advanced solid tumors | Cancer Research | American Association for Cancer Research (aacrjournals.org)
Sponsor: IQVIA
Location: Providence Cancer Center, Santa Rosa, CA

NRG-GU009, Parallel Phase III Randomized Trials For High Risk Prostate Cancer Evaluating De-Intensification For Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (Predict-RT*)

Treatment agent: Radiotherapy
Physician: Michael N. Corradetti, MD
Study Coordinator: Beatrice Becker // beatrice.becker@providence.org // 707-932-5164
Study Resources: Study Details | Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial | ClinicalTrials.gov
Sponsor: NRG Oncology
Location: Providence Queen of the Valley Medical Center, Napa, CA

Parallel Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib as Maintenance Therapy in Two Cohorts of Metastatic Pancreatic Cancer Patients with DNA Damage Repair Defects (SWOG S2001)

Treatment agent: Olaparib +/- Pembrolizumab
Physician: Yao Yao Pollock, MD
Study Coordinator: Teresa Lund // teresa.lund@stjoe.org // 707-521-3830
Study Resources: https://clinicaltrials.gov/study/NCT04548752
Sponsor: National Cancer Institute (NCI) / SWOG Cancer Research Network
Location: Providence Cancer Center, Santa Rosa, CA

A Phase II Randomized Trial of Postoperative Adjuvant Capecitabine and Temozolimide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors (SWOG S2104)

Treatment agent: Capecitabine and Temozolimide
Physician: Yao Yao Pollock, MD
Study Coordinator: Beatrice Becker // beatrice.becker@providence.org // 707-932-5164
Study Resources: https://www.clinicaltrials.gov/study/NCT05040360
Sponsor: National Cancer Institute (NCI) / SWOG Cancer Research Network
Location: Providence Cancer Center, Santa Rosa, CA

Our Providers

Our Locations